TICKERNERD
Menu
INMINMHealthcare · Drug Manufacturers - Specialty & Generic

INM Stock Forecast: InMed Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$1.29
−1.53% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 25 of 100 as at 12 Sept 2026 — in the lower half.

Market cap
$7.1M
Ticker Nerd rank
25 / 100
Median analyst target
—
Analysts covering
0
Revenue$0.0−100.0% y/y
Operating income−$3.2M
Net income−$5.8M
Free cash flow−$3.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.0%
1M
−11.6%
YTD
+21.7%
1Y
−40.3%
From 52W high
−47.6%
From 52W low
+109.8%
$0.62
$2.46
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

INM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores InMed Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
25 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
94
Accruals
92
Issuance
57
Momentum
37
Growth
34
Revisions
25
Quality
8
Value
8
Volatility
2

Size (94): Smaller than most of the companies we track.

Volatility (2): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

INM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on INM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.50$1.00$1.50$2.00$2.50Oct 25Jan 26Apr 26Jul 26INM

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first
DateFirmActionRatingTarget
22 Dec 2021HC Wainwright & Co.InitiatesBuy—
29 Nov 2021HC Wainwright & Co.InitiatesBuy—
16 Feb 2021Roth CapitalMaintainsBuy$12 → $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. INM appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

INM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, InMed Pharmaceuticals, Inc. returned −40.3% against +17.5% for the S&P 500, dividends included.

INM vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Oct 25Jan 26Apr 26Jul 26INMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

INM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

InMed Pharmaceuticals, Inc. (INM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 74% of US stocks

Price / sales
1.4×

Cheaper than 61% of US stocks

Price / book
0.6×

Cheaper than 83% of US stocks

EV / EBITDA
0.1×

Cheaper than 60% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
−162.8%

Higher than 12% of US stocks

Net margin
−172.2%

Higher than 3% of US stocks

Returns & dividend
Return on equity
−112.6%

Higher than 12% of US stocks

Return on assets
−54.6%

Higher than 7% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

InMed Pharmaceuticals, Inc. (INM) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • InMed Pharmaceuticals, Inc. has a market value of $7.1M and an enterprise value of −$439K.

  • Revenue in the twelve months to 30 June 2026: $1.9M. The latest quarter shrank 100.0% year on year.

  • Net income over the same four quarters: −$12.6M, a −647.4% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$8.6M.

  • Shares outstanding: 5.3M.

  • Trailing P/E: 0.0×; forward P/E: −0.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • InMed Pharmaceuticals, Inc. employs 13 people — $149K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

INM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
INMInMed Pharmaceuticals, Inc.$7.1M
25
GELSGelteq Ltd.$7.5M
11
SNOASonoma Pharmaceuticals, Inc.$6.2M
32
YCBDcbdMD, Inc.$5.4M
28
SBFMSunshine Biopharma, Inc.$4.1M
61
SXTCChina Sxt Pharmaceuticals, Inc.$3.4M
11
APUSApimeds Pharmaceuticals US, Inc.$3.2M
9

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own InMed Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest INM news & analysis

InMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update

Newsfile Corp · 9 Sept 2026neutral

InMed Pharmaceuticals reported its full-year fiscal 2026 financial results for the period ended June 30, 2026, and provided a corporate update. The company noted its complete financial statements and related Management's Discussion and Analysis are available on its website and through SEDAR+ and SEC filings.

Why it matters — The fiscal-year financial results offer current, official financial data on InMed that INM watchers can review to assess the company's recent performance.

FAQ

Frequently asked questions about INM stock

How does Ticker Nerd's model rank INM?

As at 12 Sept 2026, InMed Pharmaceuticals, Inc. ranks 25 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).

What is the INM stock forecast for 2030?

No analyst covering InMed Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INM are extrapolating price history, which says nothing about the business.

How has INM stock performed over the past year?

InMed Pharmaceuticals, Inc. returned -40.3% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does InMed Pharmaceuticals, Inc. do?

InMed Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing cannabinoid-based small molecule therapies and pharmaceutical-grade cannabinoid manufacturing technologies.

What is the latest news on INM?

The most recent item we track (Newsfile Corp, 9 Sept 2026): "InMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update". InMed Pharmaceuticals reported its full-year fiscal 2026 financial results for the period ended June 30, 2026, and provided a corporate update. The company noted its complete financial statements and related Management's Discussion and Analysis are available on its website and through SEDAR+ and SEC filings.

Company

About InMed Pharmaceuticals, Inc.

InMed Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing cannabinoid-based small molecule therapies and pharmaceutical-grade cannabinoid manufacturing technologies. The company’s current work centers on research and development programs targeting Alzheimer’s disease, ocular disorders, and dermatological conditions, including epidermolysis bullosa and glaucoma. InMed Pharmaceuticals also operates a commercial segment through BayMedica, which develops proprietary methods to produce and commercialize rare cannabinoids for use in health and wellness products and other ingredient markets. Its pipeline includes specialized product candidates and manufacturing platforms designed to support both therapeutic development and cannabinoid supply. Headquartered in Vancouver, Canada, InMed Pharmaceuticals plays a niche role in the biotechnology sector by combining drug discovery with cannabinoid-focused production capabilities.

CEO Mr. Eric A. Adams B.S. Chem., M.I.B. · 13 employees · Canada · https://www.inmedpharma.com